?This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments.
(R)-ketamine: A new rapid-acting
antidepressant.- (2R,6R)-hydroxynorketamine, a metabolite of ketamine: the
antidepressant actions and the mechanisms.- Predictable biomarkers for
rapid-acting antidepressant response to ketamine.- Nitrous Oxide: an old
compound with emerging psychotropic properties.- Novel AMPA receptor
potentiators TAK-137 and TAK-653 as potential rapid-acting
antidepressants.- AMPA receptor potentiators as potential rapid-acting
antidepressants.- mGlu2/3 receptor antagonists as rapid-acting
antidepressants.- Antidepressant effects of the muscarinic receptor
antagonist scopolamine: Clinical and preclinical review.
First Name Kenji Last Name Hashimoto Institution - Chiba University Center for Forensic Mental Health Department - Division of Clinical Neuroscience City Chiba 260-8670 State Chiba Country Japan Email hashimoto@faculty.chiba-u.jp
Kenji Hashimoto, PhD
Chiba University, Chiba, Japan
Dr. Hashimoto is a professor and vice-director of Chiba University Center for Forensic Mental Health from 2005. Dr. Hashimoto graduated from Faculty of Pharmaceutical Sciences at Kyushu University, and received PhD. After Dr. Hashimoto worked at Fukuyama University, National Institutes of Health (NIH)/National Institute of Drug Addiction (NIDA)(Baltimore, MD, USA) and Pharmaceutical company, he moved at Chiba University Graduate School of Medicine from 2001. Dr. Hashimoto works on the development of novel therapeutic drugs for psychiatric and neurological disorders. Dr. Hashimoto published more than 550articles in PubMed listed publications. Dr. Hashimoto focus on the molecular and cellular mechanisms of ketamines antidepressant actions.
